Relay Therapeutics, Inc. · NASDAQ:RLAY
Relay Therapeutics — Merger or Acquisition (December 2020)
8 slides from Relay Therapeutics's merger presentation, Dec 14, 2020
Slide 1: Genentech Global Collaboration for RLY-1971
Genentech Global Collaboration for RLY-1971 December 2020 Confidential | © 2020 Relay Therapeutics Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, includin
Slide 3: RLY-1971 – Optimized Pharmacology for an Attractive Cancer Target
RLY-1971 – Optimized Pharmacology for an Attractive Cancer Target Confidential | © 2020 Relay Therapeutics SHP2 is a recurrently mutated oncogenic phosphatase KRAS G12C mutant NSCLC xenograft NCIH358 cell line Deep tumor regressions achieved with a continuous daily dose of RLY-1971 % Change in Tumor
Slide 4: RLY-1971 Pre-Clinical Data Demonstrate Potential Utility in Multiple Combinations
RLY-1971 Pre-Clinical Data Demonstrate Potential Utility in Multiple Combinations Confidential | © 2020 Relay Therapeutics KRAS G12C xenograft + KRAS G12Ci NCI-H358 cell line ALKi resistant NSCLC xenograft + ALKi NCI-H3122 cell line In vivo proof-of-concept that RLY-1971 synergizes with other target
Slide 5: Genentech Global Collaboration for RLY-1971
Genentech Global Collaboration for RLY-1971 Confidential | © 2020 Relay Therapeutics Potential for multiple combinations with Genentech’s pipeline, including its clinical stage KRAS G12C inhibitor, GDC-6036 Genentech’s global footprint and deep expertise in oncology make them the perfect partner Rel
Slide 6: Relay Tx and Genentech – Key Deal Terms
Relay Tx and Genentech – Key Deal Terms Confidential | © 2020 Relay Therapeutics Exclusive License Profit Share Low-to-mid teen royalties on global net sales Royalties Low-to-mid teen royalties on OUS net sales Up to $695M in total milestones Milestones Up to $410M in total milestones Relay Tx share
Slide 7: Upcoming Milestones and Financials
Upcoming Milestones and Financials Confidential | © 2020 Relay Therapeutics Future opportunities across other therapeutic areas, including genetic diseases, precision immunology, and precision neuroscience Key Milestones Future updates coordinated with Genentech Financials RLY-1971 (SHP2) RLY-4008 (
Slide 8: Confidential | © 2020 Relay Therapeutics
Confidential | © 2020 Relay Therapeutics
Relay Therapeutics — Merger or Acquisition (December 2020) on 6ix